Inflammatory Breast Cancer: a Separate Entity
- 52 Downloads
Purpose of Review
Inflammatory breast cancer (IBC) is an uncommon but highly aggressive subtype of breast cancer that contributes significantly to breast cancer–related mortality. In this review, we provide an overview of the clinical and molecular characteristics of IBC, and highlight some areas of need for ongoing research.
The disease is characterized by florid tumor emboli that obstruct dermal lymphatics, leading to swelling and inflammation of the affected breast. Recent studies have focused on tumor cell intrinsic features, such as signaling through pathways involved in growth and stem-like behavior, as well as extrinsic features, such as the immune system, that can be leveraged to develop new potential therapies.
Key efforts have led to an increase in awareness of the disease as well as new insights into IBC pathogenesis. However, there is a strong need for new therapies designed specifically for IBC, and many unanswered questions remain.
KeywordsInflammatory breast cancer Locally advanced breast cancer Tumor emboli Dermal lymphatic invasion Clinical trials
Compliance with Ethical Standards
Conflict of Interest
Jennifer M. Rosenbluth declares that she has no conflict of interest.
Beth A. Overmoyer has received clinical trial support from Incyte, Eisai, and Genentech.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors. If this does pertain to clinical trials for IBC, Dr. Overmoyer has designed these studies which are mentioned in the aticle.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 2.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. France: Springer; 2010.Google Scholar
- 3.Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual, 8th ed. Springer International Publishing: American Joint Commission on Cancer; 2017.Google Scholar
- 15.•• Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, et al. International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018;9(8):1437–47. This paper discusses guidelines for the diagnosis and management of IBC developed by a panel of experts from high-volume centers who treat IBC. Areas of controversy were also highlighted. PubMedPubMedCentralGoogle Scholar
- 17.Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, et al. Metabolic characterization of inflammatory breast cancer with baseline FDG-PET/CT: relationship with pathologic response after neoadjuvant chemotherapy, receptor status, and tumor grade. Clin Breast Cancer. 2019;19(2):146–55.PubMedGoogle Scholar
- 19.Morrow RJ, Etemadi N, Yeo B, Ernst M. Challenging a misnomer? The role of inflammatory pathways in inflammatory breast cancer. Mediat Inflamm. 2017;2017:4754827.Google Scholar
- 21.Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(19):2018–24.Google Scholar
- 22.Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.PubMedGoogle Scholar
- 23.Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.PubMedGoogle Scholar
- 24.Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27–35.PubMedGoogle Scholar
- 25.Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedGoogle Scholar
- 26.•• Pernas S GS, Harrison BT, Hu J, Johnson N, Regan M, Chichester LA, Nakhlis F, et al. editors. Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade. Proceedings of the 2018 San Antonio Breast Cancer Symposium, Philadelphia (PA); 2018. Analysis of data from a neoadjuvant clinical trial for HER2+ IBC that suggests that immune activation after 1 week of pre-operative dual-HER2 blockade predicts pCR in IBC. Provides further support for clinical trials of immunomodulatory agents as therapy for IBC. Google Scholar
- 27.•• Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, et al. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer. JAMA Oncol. 2018;4(9):1207–13. This study of an EGFR inhibitor in combination with chemotherapy demonstrated a high pCR rate in patients with HER2-negative inflammatory breast cancer. PubMedPubMedCentralGoogle Scholar
- 29.Overmoyer B, Polyak K, Brock J, Van Poznak C, King T, Haddad T, et al. Study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer: Translational Breast Cancer Research Consortium Trial 039. San Antonio: San Antonio Breast Cancer Symposium; 2017.Google Scholar
- 37.Chen H, Wu K, Wang M, Wang F, Zhang M, Zhang P. A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: a large population-based study in the Surveillance, Epidemiology, and End Results database 18. Breast. 2017;35:48–54.PubMedGoogle Scholar
- 42.Nakhlis F, Regan M, Chun YS, Dominici LS, Jacene HA, Yeh ED, et al. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer. San Antonio: San Antonio Breast Cancer Symposium; 2015.Google Scholar
- 45.Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, et al. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014;3(7):849–56.PubMedPubMedCentralGoogle Scholar
- 46.•• Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, et al. Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 Phase I Multicenter Study. J Clin Oncol. 2018;36(13):1317–22. This is the report of the Phase I study of a PARP inhibitor given concurrently with radiotherapy, demonstrating the potential of this regimen but also underscoring the importance of long-term monitoring for toxicity. PubMedGoogle Scholar
- 49.von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–31.Google Scholar
- 50.von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.Google Scholar
- 55.Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, et al. Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis. 2017;38(3):252–60.PubMedGoogle Scholar
- 56.Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, et al. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Lett. 2013;337(1):77–89.PubMedPubMedCentralGoogle Scholar
- 60.•• Lacerda L, Debeb BG, Smith D, Larson R, Solley T, Xu W, et al. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res. 2015;17:42. This study demonstrates that co-injection with mesenchymal stem cells improves skin invasion and metastasis in a SUM149 IBC xenograft model. These features were generally not found in most prior models of IBC. PubMedPubMedCentralGoogle Scholar
- 65.Rosenbluth JMZI, Boedicker M, Wagle N, Dillon D, Nakhlis F, Brugge JS, et al., editors. Patient-derived organoid models of inflammatory breast cancer. San Antonio: SABCS; 2018.Google Scholar
- 71.•• Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, et al. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Res Treat. 2018;171:283–93. In this study, immunostaining of normal breast tissue from IBC patients revealed enrichment of mammary stem cells as well as macrophages. This provides additional evidence for the role of the microenvironment and host factors in IBC. Google Scholar
- 73.•• Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 2015;6(15):13506–19. This study assessed PDL1 mRNA levels in IBC samples. A high level of PDL1 was predictive of response to chemotherapy in this retrospective study. PubMedPubMedCentralGoogle Scholar
- 80.Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, et al. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res. 2009;15(21):6639–48.PubMedPubMedCentralGoogle Scholar